Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Veru Inc.（納斯達克股票代碼：VERU）是一家處於臨床後期階段的生物製藥公司，專注於開發用於保留肌肉以實現高質量減肥、腫瘤學和病毒誘發的急性呼吸窘迫綜合徵的薈萃分析報告的數據，該報告於2024年11月5日在德克薩斯州聖安東尼奧舉行。
Highlights from the presentation:
The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
演示要點：
薈萃分析的目的是確定enobosarm對肥胖老年患者身體成分的影響，這些患者曾參與過4項測量身體成分的enobosarm隨機臨床試驗，包括2期老年男性和絕經後女性、肌肉萎縮的2期晚期癌症患者和兩名伴有癌症消耗的3期晚期肺癌患者。
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
薈萃分析是針對年齡較大（≥60歲）的肥胖（體重指數≥30）的受試者進行的，與安慰劑相比，每天使用3mg的enobosarm進行治療，並進行了第84天（n=60）和第147天（n=45）的DEXA掃描以評估身體成分。
Results of DEXA scan assessments of body composition in older subjects with obesity:
At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
DEXA對老年肥胖受試者身體成分的評估結果：
在第84天，與安慰劑相比，enobosarm的3mg治療導致瘦肉質量絕對增加（0.05千克enobosarm對比-1.54千克安慰劑）和脂肪量絕對減少（-1.48千克enobosarm對比安慰劑-0.35千克）。
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
在第147天，與安慰劑相比，enobosarm的3mg治療導致瘦肉質量絕對增加（-0.79千克enobosarm對比-1.77千克安慰劑），脂肪量絕對減少（-2.05千克enobosarm對比-0.05千克安慰劑）。
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
在第147天，與安慰劑相比，通過DEXA掃描，enobosarm接受3mg治療的受試者的總體重減輕幅度更大（enobosarm爲-2.93千克，安慰劑爲-2.11千克）。
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.
Enobosarm 的耐受性總體良好，胃腸道副作用沒有增加。
